Arrowhead's 81% TG Drop Could Trigger an sNDA by Year-End-But ARWR Hinges on One Regulatory Bet

Phase 3 results make plozasiran a filing story, not just a data read

Arrowhead's Phase 3 SHASTA program has moved plozasiran closer to a real approval narrative. Median triglyceride reductions of 79% and 81% across SHASTA-3 and SHASTA-4, together with a statistically significant reduction in acute pancreatitis events, make this one of the strongest sHTG datasets to emerge so far. Management has also indicated that detailed results are expected at the ESC Congress on Aug. 30, keeping momentum focused on the next regulatory milestones.

What the Phase 3 data actually show

In approximately 750 adults with severe hypertriglyceridemia, 25 mg plozasiran given once every three months produced median triglyceride reductions of 79% in SHASTA-3 and 81% in SHASTA-4 at month 12, versus about 27% in the respective placebo groups. Both trials met their primary endpoint and all prespecified secondary endpoints, including statistically significant reductions in acute pancreatitis events. For a lipid asset, that matters because it goes beyond biomarker lowering and points toward the clinical complication clinicians most want to prevent in sHTG.

Why the debate is still open

The bullish case is straightforward: if a therapy can consistently drive very large triglyceride reductions and lower pancreatitis risk, it has the ingredients for a meaningful first-line treatment story. The main pushback is that pancreatitis reduction may still be framed as secondary evidence by regulators and payers, which could shape the label and reimbursement conversation. That makes the filing strategy and upcoming data detail more important than simple headline efficacy.

Durability, dosing, and broader lipid effects support the asset case

The long-term read is encouraging. In the two-year open-label extension, patients with severe hypertriglyceridemia still saw 83% median reduction in triglycerides, 96% achieved triglyceride levels below 500 mg/dL, and no adjudicated acute pancreatitis events occurred during two years of treatment. That suggests the triglyceride-lowering effect can be maintained over time, which is important for any chronic metabolic therapy.

Why dosing may matter commercially

Plozasiran was given as 25 mg plozasiran as a subcutaneous injection once every three months. In a condition that often requires ongoing management, quarterly dosing could be a real differentiator if it translates into better real-world adherence compared with more frequent or daily regimens.

The dataset may matter more than the platform

The extension data also showed favorable and durable improvements in remnant cholesterol, non-HDL cholesterol, and ApoB. That broadens the profile beyond triglycerides alone, but the cleanest commercial path is still likely a focused sHTG indication where the unmet need is highest and the combination of deep TG lowering and fewer pancreatitis events is most relevant.

Regulatory execution now matters more than the RNAi story

The SHASTA program and other plozasiran evidence, including MUIR-3, support development across multiple geographies. That can widen the market, but it also raises execution complexity because each agency may weigh benefit, labeling, and study design differently. For investors, the key near-term question is no longer whether the biology works. It is whether Arrowhead can convert these results into an accepted regulatory pathway.

Arrowhead's next repricing steps depend on filing execution

The stock does not need a perfect label to rerate. It needs a credible path from compelling Phase 3 data to a filed application and, eventually, a commercially meaningful niche. That filing window remains the key catalyst after Phase 3 success.

The next triggers in order

• Data detail first: The ESC presentation should strengthen the approval narrative by adding subgroup clarity, safety context, and methodological transparency.
• Regulatory acceptance next: Submission and initial FDA feedback are the bridge between a strong clinical dataset and a commercial story.
• Label strategy last: A narrower, high-unmet-need sHTG label may be more valuable than a broad, less differentiated indication.

What would challenge the thesis

A narrower label would not automatically break the case. A slower filing sequence, unclear regulatory feedback, or safety concerns in extended follow-up would. Confirmation at ESC should come in the form of clearer subgroup outcomes, no new safety signals, and enough detail to make the approval path look executable rather than purely optimistic.